| 期刊簡介 | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Current Research in Translational Medicine LetPub Score 5.1
50 ratings
Rate
Reputation 6.3 Influence 3.8 Speed 7.0 | ||||||||||||||||||||||||||||||||
| 期刊簡稱 | CURR RES TRANSL MED | ||||||||||||||||||||||||||||||||
| ISSN | 2452-3186 | ||||||||||||||||||||||||||||||||
| h-index | 54 | ||||||||||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||||||||||
| 自引率 (2023-2024) | 6.20%自引率趨勢 | ||||||||||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||||||||||
| 官方網站 | https://www.journals.elsevier.com/current-research-in-translational-medicine | ||||||||||||||||||||||||||||||||
| 在線稿件提交 | https://www.editorialmanager.com/RETRAM | ||||||||||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||||||||||
| 出版商 | Elsevier Masson | ||||||||||||||||||||||||||||||||
| 主題領域 | Biochemistry, Genetics and Molecular Biology | ||||||||||||||||||||||||||||||||
| 出版國/地區 | France | ||||||||||||||||||||||||||||||||
| 發行頻率 | |||||||||||||||||||||||||||||||||
| 創刊年 | 0 | ||||||||||||||||||||||||||||||||
| 每年文章數 | 25每年文章數趨勢 | ||||||||||||||||||||||||||||||||
| 黃金OA百分比 | 20.93% | ||||||||||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q2
| ||||||||||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2452-3186%5BISSN%5D | ||||||||||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: | ||||||||||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Current Research in Translational Medicine] 的評論 | 撰寫評論 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 19:34:08 評論於 We suggest dividing the discussion of research limitations into three parts: (1) stating the research limitations; (2) explaining the research limitations in detail; and (3) proposing future research directions or improvement solutions. Discussing research limitations in this order can help you clearly point out the deficiencies of the research without compromising its quality and credibility  (0) 讚！ | 维尔娜菲茨杰拉德  |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 11:02:00 評論於 It is still necessary for us to clearly describe the limitations of the research in our paper and explain how these limitations impact the conclusions of the paper, so that reviewers and other readers can see that we have taken into account the limitations of the study. Discussing the limitations of the research in the discussion section typically makes the article more credible. Thinking about how to overcome these limitations in future research can have a positive impact (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 深渊兴业 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 15:44:09 評論於 Is it necessary to indicate the limitations of the article in the discussion? (0) 讚！ | 深渊兴业 |
| 作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-26 13:28:34 評論於 How to write about the limitations of a discussion? (0) 讚！ | Darlene Pepys |
| 作者: 平原俊健 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2020-12-02 13:03:09 評論於 Is the magazine moving very slowly? The 17th has been submitted and it is still in the "submitted to journal" status (0) 讚！ | 平原俊健 |
| 作者: 暴风飞舟 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2019-12-15 18:58:37 評論於 Mark submitted to the Journal on the 11th, no changes yet (0) 讚！ | 暴风飞舟 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
